Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis

Figure 4 Cohort meta-analysis (random effects model) of outcomes in the non-randomized controlled trials. A: Change in alanine aminotransferase levels; B: Change in aspartate aminotransferase levels; C: Proportion of patients with an improvement in disease. CI: Confidence interval; ALT: Alanine aminotransferase; MN: Mean change from baseline; RE: Random effects.